Anne-kirsti Aksnes
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Normal Tissue Dosimetry of Intraperitoneal 224Ra Microparticle Therapy: Data from First-in-Human Studies in Patients with Peritoneal Metastases.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 05, 2026
First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.
Journal: Gynecologic oncology
Published: September 30, 2025
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial.
Journal: British journal of cancer
Published: May 09, 2019
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Journal: The Lancet. Oncology
Published: December 03, 2014
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.
Journal: Breast cancer research and treatment
Published: March 24, 2014
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: December 20, 2012
A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.
Journal: Physics in medicine and biology
Published: May 02, 2012
Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.
Journal: Nuclear medicine communications
Published: April 20, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026